Posted on

DepYmed’s Developmental Compound, DPM-1001, May Lead to a Potential Treatment for Wilson’s Disease

DepYmed, Inc.

Reported by Researchers at Cold Spring Harbor Laboratory

June 29, 2018 (Farmingdale, NY) — DepYmed, Inc. in collaboration with Cold Spring Harbor Laboratory (CSHL), has reported promising preclinical experiments on a compound, DPM-1001, currently being developed by DepYmed, Inc. for the potential treatment of patients with Wilson’s Disease as well as other disorders—including certain types of cancer. The new research, performed at CSHL, was published June 26, 2018 in the journal, Genes & Development.

DepYmed continues to conduct the preclinical development requirements that are necessary to bring DPM-1001 to clinical trials and hopes have this completed in the near future.

“We look forward to bringing our portfolio of novel molecules into clinical development with the goal of improving patient lives,” says Andreas Grill, President & CEO of DepYmed, Inc. “DepYmed seeks to develop novel compounds for the treatment of cancers and rare diseases including Wilson’s Disease with the continued collaboration with Cold Spring Harbor Laboratory.”

ABOUT WILSON’S DISEASE

Wilson’s disease is a genetic disorder in which copper builds up in the body. Symptoms are typically related to the brain and liver. Liver-related symptoms include vomiting, weakness, fluid build-up in the abdomen, swelling of the legs, yellowish skin, and itchiness. Brain-related symptoms include tremors, muscle stiffness, trouble speaking, personality changes, anxiety, and seeing or hearing things that others do not.

Wilson’s disease is an autosomal recessive condition due to a mutation in the Wilson disease protein (ATP7B) gene. For a person to be affected, they must inherit an affected copy of the gene from each parent. Diagnosis may be difficult and often involves a combination of blood tests, urine tests, and a liver biopsy. Genetic testing may be used to screen family members of those affected.

Current medications used to treat Wilson’s Disease include chelating agents such as trientine and d-penicillamine and zinc supplements. Chelating agents enable the body to absorb and naturally excrete copper, which is toxic in excess.  Complications of Wilson’s disease can include liver failure, liver cancer, and kidney problems. A liver transplant may be helpful in those in whom other treatments are not effective or if liver failure occurs.

Wilson’s disease occurs in about 1 in 30,000 people. Symptoms usually begin between the ages of 5 and 35 years. Males and females are equally affected. It was first described in 1854 by Friedrich Theodor von Frerichs and is named after Samuel Wilson.

CITATION

Krishnan, N et al, “DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson’s disease” is published June 26, 2018 in Genes & Development.

ABOUT DEPYMED, INC.

DepYmed Inc., is a New York-based cancer and rare disease therapeutic development company. DepYmed is developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) with its current lead compound, MSI-1436C, in clinical development as a therapeutic candidate for HER2-positive breast cancer. In addition to PTP1B inhibitors, DepYmed has developed a portfolio of small molecules with copper chelating properties which can be applied as potential therapeutic agents for multiple diseases. DepYmed continues to develop the next generation of more potent PTP1B inhibitors / analogs as well as selective copper chelators which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory and continues to explore additional indications that may benefit from using PTP1B inhibitors and selective copper chelators as therapeutic agents.

ABOUT COLD SPRING HARBOR LABORATORY

Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program annually hosts more than 12,000 scientists. The Laboratory’s education arm also includes an academic publishing house, a graduate school and the DNA Learning Center with programs for middle and high school students and teachers. For more information, visit www.cshl.edu.

Posted on

DepYmed, Inc. Announces $2 Million Financing

DepYmed, Inc.

Completion of Series ‘A’ Round of Funding with TopSpin

October 26, 2016 (Cold Spring Harbor, NY) – DepYmed, Inc., a pharmaceutical company focused on phosphatase inhibition for multiple therapeutic applications, today announced the completion of a Series ‘A’ Round of funding with TopSpin Fund, L.P. for a total of $2 million.  At closing, $1 million was received by Depymed, and another $1 million will be provided pending the achievement of specific development milestones.

“We are very pleased to have received this investment from TopSpin, a prestigious Long Island based venture capital fund.”, said Andreas G. Grill, President and CEO of DepYmed, Inc., “We believe this investment validates our approach to treating cancer with phosphatase inhibitors and provides us with the ability to further expand our platform of PTP1B inhibitors for the potential treatment of diseases across multiple therapeutic areas.”

DepYmed, Inc. is currently conducting a phase 1 clinical trial of its lead compound, MSI-1436C (Trodusquemine), as a therapeutic candidate for HER2-positive breast cancer. The clinical study is ongoing at the Monter Cancer Center – a state of the art cancer treatment center and part of Northwell Health. DepYmed is also in preclinical development of more potent PTP1B inhibitors in collaboration with Cold Spring Harbor Laboratory exploring additional indications within oncology, metabolic diseases as well as central nervous system (CNS) indications.

In connection with the financing, Steve Winick, Managing Director at TopSpin Fund, L.P.  joined the Board of Directors at DepYmed, Inc.

Steve Winick had been with Honeywell (and the Ademco division of Pittway Corp., before its acquisition by Honeywell in 2000) for over 21 years as CTO of the security business, as well as founder and president of its wireless communications services business. Mr. Winick received a B.S. in Economics from the Wharton School of the University of Pennsylvania in 1971 and a B.S. in Electrical Engineering in 1972, also from Pennsylvania. He received his J.D. from Georgetown University Law Center and is a registered Patent Attorney.

ABOUT DEPYMED, INC.
DepYmed Inc., is a New York based therapeutic development company. DepYmed’s lead compound in development is MSI-1436C (Trodusquemine), a potent inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B). MSI-1436C is currently in clinical development as a therapeutic candidate for HER2-positive breast cancer. DepYmed continues to develop the next generation of more potent PTP1B inhibitors / analogs which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory and continues to explore additional indications that may benefit from using PTP1B inhibitors as therapeutic agents. The Company was founded through a joint venture between Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) and Cold Spring Harbor Laboratory.

ABOUT TOPSPIN FUND, L.P.
TopSpin Partners is a venture capital and private equity firm based on Long Island. TopSpin is the successor fund to the Long Island Venture Fund, a successful venture capital fund which began investing in 1995.

ABOUT COLD SPRING HARBOR LABORATORY
Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, CSHL has been an NCI-Designated Cancer Center since 1987 and is clinically affiliated with Northwell Health.  The Laboratory has produced 28 spin out companies.  A private, not-for-profit, CSHL employs 1100 people including 600 scientists, students and technicians. The Meetings & Courses Program hosts more than 12,000 scientists from around the world each year on its campuses in Long Island and in Suzhou, China. The Laboratory’s education arm also includes an academic publishing house, a graduate school and programs for middle and high school students and teachers. For more information, visit www.cshl.edu.

Posted on

DepYmed, Inc. Announces Appointment of New President and CEO

DepYmed, Inc.

Andreas G. Grill is appointed President and Chief Executive Officer

February 17, 2015 (Cold Spring Harbor, NY) – DepYmed, Inc. is pleased to announce the appointment of Andreas G. Grill as President and Chief Executive Officer. Mr. Grill joins DepYmed with over 22 years of pharmaceutical industry experience encompassing executive, scientific, operational and business development roles.

Prior to joining DepYmed, Mr. Grill founded Advanced Pharmaceutical Strategies, LLC (APS) a drug product development consulting firm working with a number companies within the cancer therapeutic area. Prior to APS, Mr. Grill dedicated 20 years within Pharmaceutical Research & Development at Forest Research Institute (FRI), a subsidiary of Forest Laboratories, Inc. (FLI). Mr. Grill concluded his FRI tenure as Executive Director, Pharmaceutical Research & Development (PR&D) leading multiple research and development departments as well as global project development teams. Mr. Grill was an FLI nominated member of multiple executive committees responsible for the leadership and direction of drug product development ranging from conception through marketing registration as well as life-cycle management. His drug development portfolio comprises a broad range of pharmaceutical indications and dosage forms including: Lexapro® (escitalopram oxalate) tablets/oral solution; Namenda® (memantine HCl) tablets/oral solution; Bystolic® (nebivolol HCl) tablets; Savella® (milnacipran HCl) tablets; Namenda XR® (memantine HCl) capsules, Teflaro® (ceftaroline fosamil); Linzess® (linaclotide) capsules; Namzaric™ (a fixed-dose combination of memantine extended-release / donepezil hydrochloride) capsules. Prior to Forest, Mr. Grill served in a scientific research capacity for Pfizer, Inc., Groton, Connecticut.

“Andreas brings his extensive drug product development and pharmaceutical marketing experience to DepYmed which will be invaluable in bringing Trodusquemine and other pipeline products into the clinic and beyond, based on the exciting preclinical research conducted to date,“ said Sam Backenroth, DepYmed Director and CFO of Ohr Pharmaceutical, Inc. “Depymed’s pipeline of allosteric PTP1b enzyme inhibitors affords the promise of novel therapies in multiple therapeutic settings.”

“We are pleased to have Andreas on board to lead this effort to bring this Cold Spring Harbor Laboratory science based discovery to patients,” said Teri Willey, DepYmed Director and Vice President for Business Development and Technology Transfer at Cold Spring Harbor Laboratory.

“I have had the unique opportunity to collaborate with the DepYmed stakeholders during the past few months,” said Mr. Grill. “We are looking forward to the upcoming clinical trial to investigate the effect of Trodusquemine on HER2 positive breast cancer and developing future effective treatment options for the significant needs of oncological patients.”

Mr. Grill will also serve on the Board of Directors at DepYmed. He continues to support the scientific community as an Advisory Board Member for Stony Brook University – Institute of Chemical Biology & Drug Discovery, Advisor for the BioStrategy Sessions at SUNY Stony Brook – Center of Biotechnology, Member of the Bioscience Advisory Board for SUNY Farmingdale as well as a member of the Board of Directors for the Farmingdale College Foundation. Mr. Grill holds a Bachelor of Science in Biochemistry from Stony Brook University, Stony Brook, NY as well as Master of Business Administration from Dowling College, Oakdale, NY.

ABOUT DEPYMED, INC.
DepYmed Inc., a joint venture of Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) and Cold Spring Harbor Laboratory, developing Trodusquemine (MSI-1436), an inhibitor of the enzyme PTP1B (protein tyrosine phosphatase 1B), as a therapeutic candidate for HER2-positive breast cancer. The continued preclinical research will be conducted under the guidance of Dr. Nicholas Tonks at Cold Spring Harbor Laboratory, who discovered and is an expert on the PTP1B enzyme.

ABOUT COLD SPRING HARBOR LABORATORY
Celebrating its 125th anniversary in 2015, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology and associated with over 30 science-based spin-out companies. Home to eight Nobel Prize winners, the private, non-profit Laboratory is more than 600 researchers and technicians strong. The Meetings & Courses program hosts more than 12,000 scientists from around the world each year on its campuses in Long Island and in Suzhou, China. The Laboratory’s education arm also includes an academic publishing house, a graduate school and programs for middle and high school students and teachers. For more information, visit www.cshl.edu.

ABOUT OHR PAHRMACEUTICAL
Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is an ophthalmology research and development company. The company’s lead product, Squalamine, is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery. The company also has a research agreement with Alcon on a sustained release program. Additional information on the company may be found at www.ohrpharmaceutical.com.